Major health agencies now recommend the systematic application of ambulatory blood pressure monitoring (ABPM) for the diagnosis of hypertension. Given the exceedingly high prevalence of nocturnal hypertension, masked and white coat hypertension and the overt inadequacy of peridialysis ( pre-, intra-and post-dialysis) BP measurements, more extensive application of ABPM for the diagnosis of hypertension in dialysis patients would appear logical. In a recent survey performed in NDT Educational, organizational problems and/or cognitive resistance emerged as important factors hindering more extensive application of ABPM and home BP by nephrologists. External validation of observations made in landmark studies in a single institution about hypertension subcategorization by ABPM is urgently needed. Furthermore, apparent cognitive resistance by nephrologists may be justified by the fact that these techniques have been insufficiently tested in the dialysis population for applicability in everyday clinical practice, tolerability, organizational impact and cost-effectiveness. We should be more resolute in abandoning peridialysis measurements for diagnosing and treating hypertension in haemodialysis patients. Home BP is a formidable educational instrument for patient empowerment and self-care, and evidence exists that this technique is superior to peridialysis values to better hypertension control as defined on the basis of ABPM. We should strive to promote more extensive application of home BP monitoring to diagnose and manage hypertension in haemodialysis patients. ABPM with novel, user friendly and better tolerated techniques is to be awaited in the near future.
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I N T R O D U C T I O N
Arterial pressure in stage G5D CKD patients is routinely measured peridialysis, i.e. before, during or after dialysis, and current knowledge on the risk of hypertension in this population is largely based on peridialytic measurements. However, it is well established that these metrics do not reflect the actual arterial pressure burden as assessed by the golden standard (ambulatory blood pressure monitoring for 44 h during the dialysis interval) [1] . Pre-dialysis BP overestimates average arterial pressure during the dialysis interval while post-dialysis BP underestimates the same parameter. This issue is further compounded by the high frequency of nocturnal [2] and masked and white-coat hypertension [3] in the dialysis population. Thus, there is a serious risk of hypertension misdiagnosis in haemodialysis patients. In one of the biggest changes to previous guidelines from the National Institute for Health and Clinical Excellence (NICE) in Great Britain, the most recent guideline by the same institute now recommends that in all individuals with a BP >140/90 mmHg or higher during an office visit, ABPM should be proposed [4] . Home blood pressure monitoring can be offered as an alternative for those unable to use ABPM. This move by NICE stimulated a thorough revision of guidelines by scientific societies and led to the establishment of a compelling set of indications for the application of ABPM by an expert committee of the European Society of Hypertension [5] (Table 1) , which substantially echoes recommendations by NICE. More recently, based on a meta-analysis funded by the US Agency for Healthcare Research and Quality [6] , the American US Preventive Services Task Force has issued a recommendation supporting ABPM. The meta-analysis showed that 5 to 65% of patients with high office blood pressure might not be truly hypertensive as defined by ABPM. An ambulatory BP monitor costs about 2000 EU (2250 US$). It was estimated that primary care physicians would need one monitor for every 2000 patients [4] , which is the average size of a general practice in most EU countries and in the USA. The cost of the monitor would be amortized in 1 year due to savings in unnecessary treatment and visits [4] . Thus, ABPM is not only useful for the diagnosis of hypertension in the community but also cost-effective. What are the implications of the new guidelines and costeffectiveness analyses of ABPM for the dialysis population? Even though the issue at stake in this Polar View is ABPM, I will discuss ABPM side by side with home BP monitoring, a simpler and less expensive technique that is proposed as an alternative to ABPM.
CA N A B P M A N D H O M E B P M O N I TO R I N G CO N T R I B U T E TO R E F I N I N G T H E P RO G N O S I S I N D I A LY S I S PAT I E N T S ?
ABPM [7] and home BP measurements [8] in dialysis patients are linearly related to the risk of death while office measurements have a complex relationship with the same outcome (see below). However, neither ABPM nor home BP convey meaningful discriminant or reclassification power over and above standard risk factors. In studies performed so far in haemodialysis patients, the independent risk (hazard rate, HR) associated with confirmed (sustained) hypertension (a 44-hour ambulatory BP of ≥135/85 mmHg and a median midweek intradialytic BP of ≥140/80 mmHg) and for home BP (>140/90 mmHg) is between 2.0 and 3.0 [7] . In order to add sufficient discriminatory power over and above other risk factors for the identification of patients who will go on to develop future events (death, cardiovascular events) and/or to improve risk classification at an individual level, risk factors should have a very high HR (in general >10) for the outcome of interest [9] . Thus, it can be excluded that ABPM or home BP per se adds meaningful predictive power to standard risk factors in dialysis patients. The same reasoning applies to ABPM application in the general population.
However, the lack of prognostic power of a given risk factor does not exclude that interventions to modify the same risk factor can produce health benefits. Therapy is an issue related to aetiology and risk factor modification rather than to risk prediction. What we expect from these techniques is that they will provide a valid guide for diagnosis and treatment of hypertension in dialysis patients. We already know very well that they play a minimal or no role in risk stratification and prognosis.
CA N W E TA K E FO R G R A N T E D T H AT T R E AT M E N T O F H Y P E R T E N S I O N I S E V E N LY A N D S E N S I B LY B E N E F I C I A L I N D I A LY S I S P AT I E N T S ?
In the early days of dialysis, when the average age of this population was 46 years and when patients with comorbidities were very often excluded from chronic dialysis programmes, high blood pressure was a direct predictor of mortality and cardiovascular events [10] . In the new millennium, the average age of the dialysis population is approaching 70 years in most economically developed countries, and blood pressure is inversely rather than directly associated with mortality in this population [11] , a phenomenon attributed to reverse causality triggered by structural heart disease. Because life expectancy is very low in old dialysis patients, the benefits of hypertension treatment cannot be taken for granted in these patients. Old age, comorbidities and frailty [12] are strong risk factors for complications and adverse effects of interventions. Treatment of hypertension may cause intradialytic hypotension (which is per se a risk factor for death) and orthostatic hypotension and falls while the benefits of lower BP levels on cardiovascular outcomes may not be immediate (see below). In such a dim scenario, the risk of harm may exceed the chances of benefit by the same interventions. Making a reliable diagnosis of hypertension with ABPM or home BP monitoring makes sense only if we are certain that treating hypertension produces tangible health benefits. This line of reasoning surfaces in Alan Jardine's CON part of this Polar View [13] . Indeed, he remarks that the pattern of cardiovascular disease is unique in this population because heart failure (a long-term sequel of systemic hypertension [14] ) and sudden death dominate the scene. He also stresses that in most studies all-cause and cardiovascular mortality were unrelated to BP. A salient point by Alan Jardine is that because BP depends on volume status it is a preferable targeting therapy based on markers of volume status and left ventricular (LV) mass and function rather than on BP. However, the usefulness of this intriguing approach still remains to be proven. The effect on health outcomes of treatment policies guided by volume status and echocardiography has been investigated even less than traditional BP-based policies. Furthermore, the BP burden is a notorious, major effector of the long-term detrimental effects of volume overload until severe LV dysfunction supervenes. Reliable knowledge of the BP burden is fundamental in clinical practice in haemodialysis patients. 
A N E X E R C I S E O F T I M E -TO -B E N E F I T A S R E L AT E D TO H Y P E R T E N S I O N D I A G N O S I S A N D T R E AT M E N T I N D I A LY S I S PAT I E N T S
The benefits of appropriate diagnosis and treatment of hypertension in high-risk patients demand juxtaposing at an individual level of life expectancy to time needed for the health benefits of antihypertensive treatment (including volume control by ultrafiltration and reduction in salt intake and drug therapy) materialization. Today, the average age of the dialysis population in most European and North American countries is over 60 years and is approaching 70 years. A typical example of today's dialysis patient is a 68-year-old male with a renal disease of unknown aetiology and a functioning fistula, a smoker with no history of cancer, who had had a myocardial infarction, with serum CRP of 13 mg/dL, serum ferritin 323 mg/dL, BMI 28, creatinine 650 Mol/L (7.35 mg/dL), serum albumin 3.4 mg/dL and calcium 2.3 mMol/L. According to a recent, well-validated risk calculator in the dialysis population [15] , the 1-year death probability of this patient is about 15% (the average mortality rate in the ERA-EDTA Registry) which coincides with a life expectancy of 6.6 years (life expectancy 1/mortality). In general, the benefits of cardiovascular therapies appear early on when treatment is applied, but in some studies very long time-lags to cardiovascular benefit (i.e. a late divergence in survival curves between the treatment and the control arm) have been registered. For example, in the ADVANCE study in type-2 diabetics, the time-lag to benefit of antihypertensive drugs ranged from 12 months (all-cause death) to 18 months (cardiovascular events) [16] . Even adopting such a long lag-time if the patient in question (expected survival 6.6 years) has a confirmed diagnosis of hypertension (e.g. hypertension as defined by ABPM or by home BP monitoring), the patient may benefit from antihypertensive treatment. Figure 1 shows that about two-thirds of the dialysis population in Europe has a death risk of 35%/year or less, i.e. a life expectancy of 2.8 years or greater, which gives sufficient time for the cardiovascular benefits of hypertension control to materialize. A recent meta-analysis remarked that the benefits of antihypertensive treatment are evident at all risk levels [17] and that in absolute terms such benefits are even greater in patients with a higher baseline cardiovascular risk, as a tenet remarked 15 years ago in a classic review of the risk of end-stage renal disease by the same cardiovascular epidemiologists [18] . Provided that dialysis patients have a sufficiently long survival, there is no reason to believe that the benefit of treatment be negated to these patients. In a recent analysis in the Chronic Renal Insufficiency Cohort (CRIC), out of dialysis systolic BP measurement predicted a linear increase in the risk of death from 110 mmHg on [19] . Even in a very high-risk condition like heart failure, when standardized BP measurements out of dialysis go down {carvedilol (−9/−8 mmHg) [20] or telmisartan (−7/−5 mmHg) [21] }, the risk of death does as well. Thus, streamlining the diagnosis and treatment of hypertension in the dialysis population has relevant potential for improving health outcomes. In his counter-deductions to the PRO contender [22] , it is clear that Alan Jardine agrees that at least home BP measurements, a method investigated by Rajiv Agarwal about 10 years ago [23] , are needed for proper diagnosis and management of hypertension in the dialysis population. Home BP costs less and is better accepted by patients. Can home BP measurements surrogate ABPM for the diagnosis of hypertension and for BP targeting in the dialysis population?
H O M E B P I N D I A LY S I S PAT I E N T S : D I A G N O S I S , M O N I TO R I N G , E M P OW E R M E N T
Estimates based on home BP are not only more reproducible than pre-and post-dialysis BP, and have a far better association with 44-h ABPM (i.e. the gold standard for the diagnosis of hypertension in dialysis patients) than peridialytic measurements [24] , but they are also linked to left ventricular hypertrophy and cardiovascular prognosis [25] . There is just one thorough study testing the value of home BP in haemodialysis patients [23] . In this study in 104 American patients (91% black, 70% males) treated in two centres in Indianapolis, a home BP of 150 mmHg or more had an area under the ROC curve for the diagnosis of systolic hypertension (as assessed by 44-h ABPM) of 0.82 (95% CI 0.82-0.95) [23] suggesting good diagnostic performance. However, the 150 mmHg threshold was selected post hoc to maximize the discrimination power for the diagnosis of hypertension (as defined by the gold standard) of the sensitivity -1-specificity combination in ROC curve analysis. Findings in this important study in the USA still remain to be confirmed in surveys in other health care settings and in other countries. In a recent study in an academic hypertension centre in China [26] , ABPM identified as many as 178 individuals among 442 classified as normotensive by home BP (40%) as having masked hypertension ( Figure S2 in reference F I G U R E 1 : Distribution of the predicted probability of 1-year mortality in haemodialysis patients in Europe. The figure was derived from data reported in Figure 3 in ref [15] . [26] ). Furthermore, the same technique reclassified 42 out of 61 patients with white coat hypertension by home BP (68%) as having true (sustained) hypertension [26] . Importantly, in haemodialysis patients there are no analyses focusing on the contribution of night-time BP values to prevailing 24 or 44-h ABPM average values in the same population. Given the high frequency of non-dipping and nocturnal hypertension in endstage renal disease, the problem of masked hypertension-the Achilles's heel of home BP monitoring-may be even more serious than in the general population. A thorough meta-analysis including studies in primary care and in other settings remarked that home BP monitoring has insufficient sensitivity or specificity to be recommended as a single diagnostic test [27] . Taking into account the high prevalence of nocturnal hypertension in dialysis patients, home BP in the dialysis scenario has similar or possibly greater limitations than in other health care settings. Notwithstanding being inferior to ABPM in accuracy, the fact remains that home BP is also unquestionably superior to peridialysis measurements for the diagnosis and treatment of hypertension in these patients [28] .
A B P M A N D H O M E B P I N T H E C L I N I CA L S C E N A R I O : A S U R V E Y
In an NDT Educational survey performed in March-April 2015, 278 nephrologists replied to a short questionnaire about ABPM and home BP monitoring (Figure 2 ). This sample is hardly representative of the readership of this online resource of the ERA EDTA. Rather, it represents the habits and beliefs of a group of highly motivated nephrologists who keep themselves updated also via this educational WEB site. Thus, the results of this survey should be considered as a very optimistic picture of real clinical practice. About a half of the participants had access to ABPM, which in 68% of cases was a service offered within the same department or directly managed within the renal unit. ABPM was used systematically by just 18% of participants (either for the diagnosis of hypertension or for monitoring therapy) and by an additional 29% only when pre-dialysis BP values were considered too variable. The technique was applied by 8% of nephrologists in patients with a diagnosis of heavy snoring or with overt sleep apnoea. Home BP had no better prospects in that it was used systematically by only 22% of nephrologists (35% resorted to home BP only in doubtful cases). Thus, even the most motivated nephrologists face substantial organizational problems for the application of ABPM or home BP monitoring and/or do not consider these techniques as instruments central for the diagnosis and treatment of hypertension in the dialysis population. The argument has been made that there is a cognitive dissonance and apathy among physicians dealing with hypertensive patients [29] . However, we believe that nephrologists' resistance to the call of extensive application of ABPM depends on the fact that knowledge about the use of ABPM in haemodialysis patients is still quite limited. Most information gathered so far about hypertension subcategorization by ABPM (masked, white-coat and sustained hypertension) [3] and about the validity of home BP monitoring [23] largely derives from studies performed in a single clinical research centre in the USA. External validation is still needed for findings in these careful studies to be considered generalizable and applicable to other centres worldwide. Furthermore, this technique has been insufficiently tested in the dialysis population as to applicability in everyday clinical practice, organizational impact, cost and cost-effectiveness. Organizing an internal service for ABPM in a haemodialysis unit with 60 patients has face-affordability (Box 1). In the analysis made by NICE [30] , confirming a diagnosis of hypertension by ABPM instead of office or home BP was the most costeffective option at all ages, and ABPM cost-effectiveness was corroborated by various sensitivity analyses. The key driver of cost savings was hypertension treatment costs avoided due to more accurate diagnosis (increased specificity). Being that life expectancy is much shorter in dialysis patients than in their peers in the general population, the savings are bound to be less in the dialysis scenario. Specific analyses in dialysis patients, considering the potential gain in quality-adjusted life years, are sorely needed.
W H E R E D O W E G O F R O M H E R E ?
Fresh clinical investigations on ABPM and home BP monitoring are perceived as a very urgent research call in CKD [31] . Three issues whereupon sufficient evidence and consensus exist deserve priority consideration: (i) peridialysis measurements are overtly inadequate to diagnose and treat hypertension; (ii) home BP monitoring is superior to peridialysis measurements for the diagnosis of hypertension; and (iii) depression and poor quality of life are notorious problems in ESRD [32] . In such a condition, tolerability of available ambulatory monitoring instruments is often limited, as fairly recognized also by Rajiv Agarwal [33] . Disturbed sleep (a major and overlooked problem in dialysis patients [34, 35] ), pain, skin irritation and bruising may be triggered or exacerbated by ABPM. Inferior acceptability is a trade-off of superior ABPM accuracy [36] .
We should be more resolute in abandoning peridialysis measurements for diagnosing and treating hypertension in haemodialysis patients. Home BP can be provisionally recommended not only for the diagnosis but also for the therapy of hypertension. Home BP is a formidable educational instrument for patient empowerment and self-care [37] . Replicating observations in patients with essential hypertension [38] , in a randomized trial comparing the effectiveness of antihypertensive treatment in a group applying home BP, and in one using pre-dialysis BP measurements as a guide to treatment, 24-h ABPM was almost identical at baseline (144 ± 14/83 ± 7 mmHg versus 145 ± 13/80 ± 6 mmHg) but substantially lower at follow-up in the group managed by home BP (135 ± 12 mmHg/76 ± 7 mmHg versus 147 ± 15 mmHg/79 ± 8 mmHg) [39] . Furthermore, home BP 24-h tracks ABPM changes brought about by ultrafiltration intensification to improve hypertension control in haemodialysis patients [33] . Awaiting a new wave of studies spanning from hypertension categorization and therapy-monitoring to service logistics and cost-effectiveness, at present ABPM may be reserved for patients with highly variable BP values and perhaps those with suspected sleep apnoea or with borderline home BP values.
As for the near future, research on less expensive, tolerable and easy-to-operate monitors based on a limited number of programmable measurements can be envisaged. A more limited number of nocturnal and daytime measurements may suffice for the reliable estimation of average night-time, daytime and 24-h BP. ABPM machines directly operated by patients and/or by their health care tenders may allow more extensive testing of ABPM in the dialysis population in the clinical scenario. Telemonitoring is already a reality in hypertension research [40] .
We should strive to promote more extensive application of home BP monitoring to diagnose and manage hypertension in haemodialysis patients. ABPM with novel, user friendly and better tolerated techniques can be expected in the near future.
CO N F L I C T O F I N T E R E S T S TAT E M E N T
The authors declare that they have no conflict of interest in relationship to the content of this manuscript. Organizational and cost problems with ABPM in a typical dialysis unit managing 60 patients If ABPM is elected as the major instrument to diagnose hypertension and monitor therapy, 3 ABPM per patient per year may be needed (180 ABPM recordings per year in all). The average time demanded for patient education, set-up, detachment and data handling of ABPM recording and equipment maintenance can be estimated to be about 30 min per record.
The total time for maintaining an ABPM service in a dialysis unit with 60 patients is about 90 h per year, i.e. 2.5 weeks of a full-time technician.
According to NICE [30] , the cost* of confirming a diagnosis of hypertension with a single 24 h ABPM is EU 73 (£53.40) per patient.
The total cost of an ABPM service in a dialysis unit with 60 patients (73 EU per test × 180 tests) is 13 340 EU. The lifetime of the machine is assumed to be 5 years with no resale value, a discount rate of 3.5% and 125 uses per year.
*Including device cost, maintenance and health care professional time.
